Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Aqua Bio Technology Capital/Financing Update 2024

Feb 5, 2024

3535_rns_2024-02-05_651ef44a-869c-469a-aa86-e97e7b648aa1.html

Capital/Financing Update

Open in viewer

Opens in your device viewer

Aqua Bio Technology ASA: Subsequent Offering - Further information and start of subscription period

Aqua Bio Technology ASA: Subsequent Offering - Further information and start of subscription period

5.2.2024 07:38:04 CET | Aqua Bio Technology ASA | Additional regulated

information required to be disclosed under the laws of a member state

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR

INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE UNITED

STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR

DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER

OF ANY OF THE SECURITIES DESCRIBED HEREIN

Reference is made to the stock exchange announcements by Aqua Bio Technology ASA

("ABT" or the "Company") on 30 and 31 January 2024 regarding the completion of a

private placement that raised approximately NOK 12.46 million in gross proceeds

(the "Private Placement") and a subsequent offering of new shares in the Company

(the "Subsequent Offering").

The Subsequent Offering consists of an offering of up to 1,000,000 new shares in

the Company (the "Offer Shares") directed towards the shareholders of the

Company as of 30 January 2024 (as registered in the VPS on 1 February 2024) (the

"Record Date"), except; (i) shareholders that subscribed for shares in the

Private Placement, and (ii) shareholders who are resident in a jurisdiction

where such offering would be unlawful, or would require any prospectus filing,

registration or similar action (the "Eligible Shareholders").

In addition, the following types of investors shall have a secondary right to

subscribe for the Offer Shares; (i) ABTEC shareholders and investors that

participated in the Private Placement, and (ii) other subscribers without

Subscription Rights (as defined below), subject to a minimum allocation of at

least NOK 5,000 (jointly, the "Secondary Subscribers").

The subscription period in the Subsequent Offering commences today, on 5

February 2024 at 09:00 hours (CET) and will end on 9 February 2024 at 16:30

hours (CET) (the "Subscription Period"). The subscription price per Offer Share

is NOK 5.00 (the "Subscription Price"), which is equal to the subscription price

in the Private Placement. If fully subscribed, the Subsequent Offering will

raise gross proceeds of NOK 5,000,000.

In the Subsequent Offering, Eligible Shareholders, will be granted

non-transferable subscription rights (the "Subscription Rights") that, subject

to applicable law, provide preferential rights to subscribe for and be allocated

Offer Shares at the Subscription Price.

The Eligible Shareholders will be granted 0,029 Subscription Rights for each

existing share registered as held by such Eligible Shareholder as of the Record

Date, rounded down to the nearest whole number of Subscription Rights. Secondary

Subscribers will not be granted Subscription Rights. Each whole Subscription

Right provides a preferential right to subscribe for, and be allocated, one

Offer Share at the Subscription Price. Over-subscription will be permitted.

Other than subscriptions from Secondary Subscribers, subscription without

Subscription Rights will not be permitted.

The Subscription Rights must be used to subscribe for Offer Shares before the

expiry of the Subscription Period on 9 February 2024 at 16.30 hours (CET).

Subscription Rights that are not used to subscribe for Offer Shares before 16.30

hours (CET) on 9 February 2024 will have no value and will lapse without

compensation to the holder.

Completion of the Subsequent Offering is subject to, inter alia, approval from

the company's board of directors, including with respect to issuance of

allocated Offer Shares.

An invitation letter (the "Invitation Letter") and a company presentation has

been prepared in connection with the Subsequent Offering, which provides further

information on the Company and its business, sets out the terms and conditions

for the Subsequent Offering and includes a description of certain risk factors

pertaining to the Company, its shares and the Subsequent Offering.

The Invitation Letter and the company presentation is attached hereto, and will

also be made available at websites of Norne Securities AS, www.norne.no/ABTEC -

http://www.norne.no/ABTEC.

Norne Securities AS is acting as Settlement Agent for the Subsequent Offering.

Advokatfirmaet CLP DA is acting as legal counsel to the Company in the

Subsequent Offering.

* * *

For further information, please contact Håvard Lindstrøm, CEO, telephone +47 941

32 288.

Aqua Bio Technology (ABT) is developing and commercializing sustainable

biotechnology for use in skin care products. ABT's cosmetics ingredients are

highly effective and they provide the cosmetics industry with natural

alternatives to traditional ingredients. ABT is also marketing and distributing

natural skin care products developed by partners towards consumers and

professional users. ABT's focus on commercialization and development of natural

ingredients and natural skin care products has been, and will continue to be, an

important part of the Company's strategy going forward. Aqua Bio Technology is

listed on the Euronext Expand market of the Oslo Stock Exchange.

DISCLOSURE REGULATION

This information is subject of the disclosure requirements pursuant to section

of 5-12 of the Norwegian Securities Trading Act.

DISCLOSURE REGULATION

This information is subject of the disclosure requirements pursuant to section

of 5-12 of the Norwegian Securities Trading Act.

CONTACTS

* Håvard Lindstrøm, 004794132288, [email protected]

ABOUT AQUA BIO TECHNOLOGY ASA

Aqua Bio Technology (ABT) is developing and commercializing sustainable

biotechnology for use in skin care products. ABT's cosmetics ingredients are

highly effective and they provide the cosmetics industry with natural

alternatives to traditional ingredients. ABT is also marketing and distributing

natural skin care products developed by partners towards consumers and

professional users. Aqua Bio Technology is listed on Euronext Expand.

ATTACHMENTS

Download announcement as PDF.pdf -

https://kommunikasjon.ntb.no/ir-files/17847556/2887/4024/Download%20announcement

%20as%20PDF.pdf

Aqua Bio Technology Company Presentation Subsequent Offering.pdf -

https://kommunikasjon.ntb.no/ir-files/17847556/2887/4022/Aqua%20Bio%20Technology

%20Company%20Presentation%20Subsequent%20Offering.pdf

Invitation Letter dated 5 February 2024.pdf -

https://kommunikasjon.ntb.no/ir-files/17847556/2887/4023/Invitation%20Letter%20d

ated%205%20February%202024.pdf